Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 11/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496064 | 0.92 | ELANE (0.47) | ELANECTRB1TACR1 | |
| SCHEMBL6505790 | 0.91 | ELANE (0.44) | ELANECTRB1TACR1 | |
| SCHEMBL6500724 | 0.91 | ELANE (0.43) | ELANECTRB1TACR1 | |
| SCHEMBL6805565 | 0.90 | ELANE (0.43) | ELANECTRB1TACR1 | |
| SCHEMBL6506622 | 0.87 | ELANE (0.46) | ELANECTRB1TACR1 | |
| SCHEMBL7840392 | 0.87 | LMNA (0.46) | ELANECTRB1TACR1 | |
| SCHEMBL6498129 | 0.86 | ELANE (0.44) | ELANECTRB1TACR1 | |
| SCHEMBL6497451 | 0.84 | ELANE (0.42) | ELANECTRB1TACR1 | |
| SCHEMBL7841675 | 0.84 | ELANE (0.48) | ELANECTRB1 | |
| SCHEMBL7444283 | 0.83 | ELANE (0.51) | ELANECTRB1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |